US.BDX · Becton Dickinson

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.084524317406143,
        "turnoverUsdM": 276.48848896000004,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BDX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 179.7022,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4.2,
      "take_profit_price": 196.896,
      "target_multiplier": 1.9,
      "technical_strength": 1.78,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.169048634812286,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 64.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 59.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 185.2565,
    "ma50": 168.5376,
    "close": 187.52,
    "prevClose": 187.12,
    "avgVolume20": 1754387,
    "volumeRatio": 0.84,
    "changePercent": 0.21
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": -0.014142315643640435,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 2,
      "vol_ratio": 0.8157095318840539,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.0606770573336533,
      "volat_points": 0,
      "day_range_pct": 0.023064259812286644,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 64.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 56,
        "contribution": 2.8
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 53.33,
        "contribution": 8
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 18,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 60,
        "contribution": 18
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 59.4,
    "details": [
      "基本面分析總分: 2.8/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 8/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 18/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 2.8,
      "資金流": 13.2,
      "市場環境": 8,
      "情緒分析": 4,
      "技術信號": 18,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 276.48848896000004,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 3.2,
          "obvPoints": 1.6,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BDX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 1.7999999999999998,
            "details": {
              "qqq": {
                "ma20": 717.5630035,
                "ma50": 710.8924000399999,
                "name": "QQQ",
                "close": 709.23999,
                "points": 0.4
              },
              "spy": {
                "ma20": 768.9759949000002,
                "ma50": 755.34080062,
                "name": "SPY",
                "close": 765.15997,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.084524317406143,
          "atrPoints": 3,
          "cciPoints": 3.2,
          "vixPoints": 0,
          "marketTrendPoints": 1.7999999999999998
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141281776,
                "url": "https://finnhub.io/api/news?id=2f1b17084b151b718d76db87b27393bf4e58e225aa9b459c14e656bb2f0102a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...",
                "category": "company",
                "datetime": 1787357437,
                "headline": "Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends"
              },
              {
                "id": 141281777,
                "url": "https://finnhub.io/api/news?id=5d979822df07bfb775e40ae865aa76e338396978b09632b2f3149d5750dcc8f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...",
                "category": "company",
                "datetime": 1787353919,
                "headline": "Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks"
              },
              {
                "id": 141281771,
                "url": "https://finnhub.io/api/news?id=f2237a51bc1885d9db19f32f63990e7dfd01b872e2eb46e336cdb6805393d8d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...",
                "category": "company",
                "datetime": 1787314239,
                "headline": "Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh"
              },
              {
                "id": 141281778,
                "url": "https://finnhub.io/api/news?id=e7adcedb141ab46bd93163e2536b035f1d90bc75f1cf4cfe9ac78f80f75695ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.",
                "category": "company",
                "datetime": 1787246580,
                "headline": "BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study"
              },
              {
                "id": 141209513,
                "url": "https://finnhub.io/api/news?id=318af3ce9d68f4d59c789d9468e33cee99853f72596451c8a34c2d7d1c3e5790",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.",
                "category": "company",
                "datetime": 1786646640,
                "headline": "Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH"
              },
              {
                "id": 141177793,
                "url": "https://finnhub.io/api/news?id=70dc677a27f0a639b4eb25b732786e9e34e2b7c06784d2bfbe25cae937204911",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "On August 6, Jim Cramer highlighted Becton, Dickinson and Company (NYSE:BDX) on CNBC’s Mad Money following its third-quarter fiscal 2026 financial report and said: This morning, we got a very strong quarter from BD. That’s the big medical technology and supply play… That was formerly known as Becton, Dickson. This was the first full quarter […]",
                "category": "company",
                "datetime": 1786384393,
                "headline": "Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance"
              },
              {
                "id": 141164545,
                "url": "https://finnhub.io/api/news?id=44f469db2ba4ab532ebcd6bf5ad440c04106be3c1ee1309f5134b752b52ce9e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson has seen its analyst fair value estimate move from US$181.23 to US$189.58, signaling a refreshed price target framework that investors are watching closely. This shift reflects how recent research is weighing the solid fiscal Q3 beat, product updates, and mixed views on 2027 utilization and margin risk. As you read on, you will see how these moving pieces shape the evolving narrative around Becton Dickinson and what that could mean for your own assessment of the stock. Stay...",
                "category": "company",
                "datetime": 1786252239,
                "headline": "Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views"
              },
              {
                "id": 141163150,
                "url": "https://finnhub.io/api/news?id=3000ac72501f771df79c06aee4f6d979ea4e11e11a74e9ed7a616f07a0d55fa7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company recently reported third-quarter fiscal 2026 results, with sales rising to US$4,983 million while net income fell to US$377 million, and modestly raised its full-year outlook for low single-digit plus GAAP revenue growth. Alongside these earnings, BD highlighted strong momentum in biologic drug delivery and GLP-1–related partnerships, including a new semaglutide pen collaboration with EMS in Brazil, underscoring the growing role of its Vystra Injection Pen...",
                "category": "company",
                "datetime": 1786234852,
                "headline": "Why Becton Dickinson (BDX) Is Up 6.8% After Q3 Beat And GLP-1 Delivery Partnerships"
              }
            ],
            "raw_source": [
              {
                "id": 141379530,
                "url": "https://finnhub.io/api/news?id=de9681a0ee09a77cf542eab958e12b5cad3038528e2ac5c18cac277bcda9770e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.",
                "category": "company",
                "datetime": 1788375156,
                "headline": "The Wide Divide Priced Into Boston Scientific Stock"
              },
              {
                "id": 141360880,
                "url": "https://finnhub.io/api/news?id=9f26bd8922432f5a0314cbcbab75d980716eaa1f1418c04dae1e6c70cefd2ab9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.",
                "category": "company",
                "datetime": 1788227277,
                "headline": "The Peer-Group Mispricing Sitting On BSX Stock"
              },
              {
                "id": 141360870,
                "url": "https://finnhub.io/api/news?id=3940eba2f9e552a33646a0657cfce9c2e5a582261d24899fe708d82efeab8c82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.",
                "category": "company",
                "datetime": 1788195506,
                "headline": "Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends"
              },
              {
                "id": 141363785,
                "url": "https://finnhub.io/api/news?id=52a212ee258f5c9d57aa79de1171a3e3e1c53086a47c9d6dea706f68d5ead932",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "The funding answers a documented gap. Hazardous drug classification remains fragmented across the NIOSH list, USP General Chapter <800>, ISOPP standards and European directives - frameworks that diverge in scope, definition and enforceability.",
                "category": "company",
                "datetime": 1788194700,
                "headline": "Four Industry Sponsors Commit $100,000 to Launch the Medicinal Hazard Data Standardization Consortium"
              },
              {
                "id": 141360981,
                "url": "https://finnhub.io/api/news?id=7d5f22cbef8e157ea1ba869d201eb992d906f5ee88dcf71ac0c3a75b51a38721",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Jim Cramer just put a Brazilian mining giant in the same sentence as cryptocurrency, and his reasoning has everything to do with where he thinks inflation is headed next.",
                "category": "company",
                "datetime": 1788191425,
                "headline": "Jim Cramer Calls This Mining Stock an Inflation Hedge “Just as Good as Crypto”"
              },
              {
                "id": 141356087,
                "url": "https://finnhub.io/api/news?id=fdddf9d19eeb7556232b1d51c414a8c6fc8c2694dfd1ae7bff42c10e2cd63df0",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "B of A Securities  analyst Travis Steed   maintains Becton Dickinson (NYSE:BDX) with a Neutral and raises the price target from $185 to $200.",
                "category": "company",
                "datetime": 1788183564,
                "headline": "B of A Securities Maintains Neutral on Becton Dickinson, Raises Price Target to $200"
              },
              {
                "id": 141336283,
                "url": "https://finnhub.io/api/news?id=d92db7b94ab38deb8d45bd11ce337de7df789b48d477823807203626cf4038b8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Dividend Aristocrats (NOBL) nearly match SPY in 2026, with top gainers, rising dividend growth, and 29 undervalued picks—see which to buy now.",
                "category": "company",
                "datetime": 1787894920,
                "headline": "Best Dividend Aristocrats For September 2026"
              },
              {
                "id": 141361650,
                "url": "https://finnhub.io/api/news?id=9d48bf108baf3cbf621771e0479bfd36e732a64ca11aeee9d74c79082830da73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "U.S. electrophysiology growth slowed sharply and standalone WATCHMAN referrals declined in the same window, leaving the rest of Boston Scientific unable to maintain its growth-stock multiple.",
                "category": "company",
                "datetime": 1787851753,
                "headline": "Has BSX Stock Fallen Far Enough To Buy?"
              },
              {
                "id": 141362225,
                "url": "https://finnhub.io/api/news?id=bf2d640e767699ec5031bd72e404bb43a15159613842c3a3ce6cb260cf29de4e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients treated across 33 active U.S. sites, triggering the first planned interim analysis. This milestone places enr",
                "category": "company",
                "datetime": 1787831400,
                "headline": "BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation"
              },
              {
                "id": 141363787,
                "url": "https://finnhub.io/api/news?id=0393fb4286881b8cdc9f393340080e70bdb7877bb6fd259aa7311c0ba2d1079f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. Eastern Time.",
                "category": "company",
                "datetime": 1787778900,
                "headline": "BD to Present at Wells Fargo 21st Annual Healthcare Conference"
              },
              {
                "id": 141362447,
                "url": "https://finnhub.io/api/news?id=484896653bda1e33aa9eee763cb7174ea64c0aa188ed308c9504b6da583e96d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "For long-suffering owners of Boston Scientific, here’s how to get paid a meaningful cash income now, yours to keep no matter what, in exchange for capping your gains at a higher price.",
                "category": "company",
                "datetime": 1787777512,
                "headline": "Time To Squeeze 14% Yield Out Of Battered BSX Stock?"
              },
              {
                "id": 141322555,
                "url": "https://finnhub.io/api/news?id=fbc0fbca0d6d10fe9adb87c1b803cba253c534273106bbab742332765ee76728",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth.",
                "category": "company",
                "datetime": 1787677537,
                "headline": "The Floor Under BSX Stock Is Being Tested Again"
              },
              {
                "id": 141318019,
                "url": "https://finnhub.io/api/news?id=c5c25081435770e6bbefd0d753fa582441539bcf14cad848ec9e609bec944b8e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1431876780/image_1431876780.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Omnicell, Inc. is rated a Hold; it faces near-term headwinds, with YoY revenue contraction, for the first time in seven quarters. Read more on OMCL stock here.",
                "category": "company",
                "datetime": 1787674356,
                "headline": "Omnicell: Offers Good Value, But Uncertainty Remains"
              },
              {
                "id": 141314075,
                "url": "https://finnhub.io/api/news?id=cffee9de1f9c3c33dbc7f50b1cfc92908d0a7791b14fc63ba2cec5a04d3d6cb8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1285071364/image_1285071364.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.",
                "category": "company",
                "datetime": 1787613074,
                "headline": "The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products"
              },
              {
                "id": 141363788,
                "url": "https://finnhub.io/api/news?id=035aa6b555e77e46f8b870a76caf03d55fa32ec6f77e1225d59f4fafc8e995b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Waters' (WAT) Q4 guidance is conservative, as there is no inherent reason for legacy Waters' growth",
                "category": "company",
                "datetime": 1787588044,
                "headline": "Waters' Q4 Guide Conservative, 2027 Growth Could Reach High Single Digits, RBC Says"
              },
              {
                "id": 141322560,
                "url": "https://finnhub.io/api/news?id=8709dc095ddd161daa91d3a51dbfe911ac63dd53a225916c372e4403e7ec998d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.",
                "category": "company",
                "datetime": 1787581560,
                "headline": "Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?"
              },
              {
                "id": 141307500,
                "url": "https://finnhub.io/api/news?id=32b08bbe296e7cb212fd1ae7c5aebca8ee10a12f8968f1cb43ac3b54896393a6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Dividend Kings beat the S&P 500 YTD, with 30 topping SPY and 25 looking undervalued with 10%+ return potential.",
                "category": "company",
                "datetime": 1787547151,
                "headline": "Best Dividend Kings: August 2026"
              },
              {
                "id": 141281776,
                "url": "https://finnhub.io/api/news?id=2f1b17084b151b718d76db87b27393bf4e58e225aa9b459c14e656bb2f0102a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...",
                "category": "company",
                "datetime": 1787357437,
                "headline": "Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends"
              },
              {
                "id": 141281777,
                "url": "https://finnhub.io/api/news?id=5d979822df07bfb775e40ae865aa76e338396978b09632b2f3149d5750dcc8f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...",
                "category": "company",
                "datetime": 1787353919,
                "headline": "Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks"
              },
              {
                "id": 141281771,
                "url": "https://finnhub.io/api/news?id=f2237a51bc1885d9db19f32f63990e7dfd01b872e2eb46e336cdb6805393d8d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...",
                "category": "company",
                "datetime": 1787314239,
                "headline": "Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh"
              },
              {
                "id": 141281778,
                "url": "https://finnhub.io/api/news?id=e7adcedb141ab46bd93163e2536b035f1d90bc75f1cf4cfe9ac78f80f75695ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.",
                "category": "company",
                "datetime": 1787246580,
                "headline": "BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study"
              },
              {
                "id": 141278185,
                "url": "https://finnhub.io/api/news?id=b6f5547aae60787470f795a553206b912e475489277993b14623fbbb126e01ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.",
                "category": "company",
                "datetime": 1787240880,
                "headline": "Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?"
              },
              {
                "id": 141265659,
                "url": "https://finnhub.io/api/news?id=72621766b3ba2eda3a73f80fafbf5c9b1ca88952ff8902906361281dbde1b406",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Becton-Dickinson.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "FDA alerts Becton Dickinson customers to remove recalled Huons sodium chloride ampules from convenience kits. No injuries reported.",
                "category": "company",
                "datetime": 1787146163,
                "headline": "What's Going On With Becton Dickinson Stock Wednesday?"
              },
              {
                "id": 141254663,
                "url": "https://finnhub.io/api/news?id=463574e3580ffb9f589901afe1e81274ac05739e4fc0c1300094be1add36c7be",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-convenience-kit-issue-becton-dickinson",
                "category": "company",
                "datetime": 1787070386,
                "headline": "FDA Issues Early Alert For High-Risk Issue With Becton Dickinson Convenience Kits; Becton Dickinson Advises Removal Of Recalled Components From Convenience Kits; Warns Against Use Of Sodium Chloride Ampules In Affected Bd Kits"
              },
              {
                "id": 141251970,
                "url": "https://finnhub.io/api/news?id=4364ba6127479c07f5699a16fac7cbec7765cc2acfb197a9f0960759f80cbeac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.",
                "category": "company",
                "datetime": 1786998600,
                "headline": "BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire"
              },
              {
                "id": 141251971,
                "url": "https://finnhub.io/api/news?id=5d59e7c1edd06ddbda2ed3402c661cfaba7913f97d47417d39994d445823ca9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1786981762,
                "headline": "Are Wall Street Analysts Predicting Becton, Dickinson and Company Stock Will Climb or Sink?"
              },
              {
                "id": 141251978,
                "url": "https://finnhub.io/api/news?id=6a679e9dc3223f5f4d26900c4cb64486a33c4d0b9199983538ecbbe0d87ec892",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.",
                "category": "company",
                "datetime": 1786735380,
                "headline": "WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?"
              },
              {
                "id": 141210844,
                "url": "https://finnhub.io/api/news?id=2bf736f8c82a4e2be8402c591dd67c6328e0044a4c9301341ce2ff92fa7cc5f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.",
                "category": "company",
                "datetime": 1786656117,
                "headline": "How Much More Can Boston Scientific Stock Move After Losing Half Its Value?"
              },
              {
                "id": 141209513,
                "url": "https://finnhub.io/api/news?id=318af3ce9d68f4d59c789d9468e33cee99853f72596451c8a34c2d7d1c3e5790",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.",
                "category": "company",
                "datetime": 1786646640,
                "headline": "Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH"
              },
              {
                "id": 141209552,
                "url": "https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"
              },
              {
                "id": 141208353,
                "url": "https://finnhub.io/api/news?id=0244c9c694007d4e9937211ed2556b17a0a629e6bd558f9db42bfdcb99e0ca05",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2227232848/image_2227232848.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Becton Dickinson’s buy rating is reaffirmed as its clinical portfolio grows, Fitch improves risk, and stock momentum returns—get the latest Wall St view.",
                "category": "company",
                "datetime": 1786630407,
                "headline": "Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing"
              },
              {
                "id": 141210225,
                "url": "https://finnhub.io/api/news?id=423fe7ea2c1239076de65c5eca506f8cc8900f3c8c77dc2afb521ed30649aa14",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/Stuttgart--Germany---03-07-2025-Smartpho.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "FDA alerts providers as Medline corrects convenience kits with recalled BD applicators due to sterility and contamination risks.",
                "category": "company",
                "datetime": 1786629609,
                "headline": "Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products"
              },
              {
                "id": 141205682,
                "url": "https://finnhub.io/api/news?id=c145b4c41426e9b58210d33118893e1097cdb793d06d7fe21c7c073bb3e302c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.",
                "category": "company",
                "datetime": 1786625700,
                "headline": "Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins"
              },
              {
                "id": 141212086,
                "url": "https://finnhub.io/api/news?id=46fc8b9320357e1303faa1963d2c6192491e6b8dbb4a6ce6ae8a011aefad67fa",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "RBC Capital  analyst Kendall Au   maintains Becton Dickinson (NYSE:BDX) with a Sector Perform and raises the price target from $180 to $190.",
                "category": "company",
                "datetime": 1786618414,
                "headline": "RBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $190"
              },
              {
                "id": 141202126,
                "url": "https://finnhub.io/api/news?id=554f4bd07663b1b9854e9df4a2804b7668b8c19b8a271fbc4748d6e95e018cb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.",
                "category": "company",
                "datetime": 1786531800,
                "headline": "BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial"
              },
              {
                "id": 141193463,
                "url": "https://finnhub.io/api/news?id=1bf62fb7bb5e82e56670edfaeb004a350ad4c7f11cd7cec590d3b4f465f7e66e",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgeryFRANKLIN LAKES, N.J., Aug. 12, 2026",
                "category": "company",
                "datetime": 1786517667,
                "headline": "Becton, Dickinson And Co. Completes Enrollment In PREVENT Clinical Trial Evaluating Phasix Mesh For Prevention Of Incisional Hernias"
              },
              {
                "id": 141177545,
                "url": "https://finnhub.io/api/news?id=900a27fb3b4f315b53cc3d81f4180c5a0e7c3de6b57840523330bdfb92cad3d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.",
                "category": "company",
                "datetime": 1786385693,
                "headline": "Boston Scientific Stock Is Priced As If WATCHMAN Were The Whole Company"
              },
              {
                "id": 141177793,
                "url": "https://finnhub.io/api/news?id=70dc677a27f0a639b4eb25b732786e9e34e2b7c06784d2bfbe25cae937204911",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "On August 6, Jim Cramer highlighted Becton, Dickinson and Company (NYSE:BDX) on CNBC’s Mad Money following its third-quarter fiscal 2026 financial report and said: This morning, we got a very strong quarter from BD. That’s the big medical technology and supply play… That was formerly known as Becton, Dickson. This was the first full quarter […]",
                "category": "company",
                "datetime": 1786384393,
                "headline": "Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance"
              },
              {
                "id": 141174297,
                "url": "https://finnhub.io/api/news?id=69abc7bda0fef2cc41514d6b8a86bc01b40e4cb7b2b108f5ac878016d42a3aad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where the dividend coverage story is quietly getting stronger.",
                "category": "company",
                "datetime": 1786369539,
                "headline": "We Said These 4 Dividend Aristocrats Could Soar. Here’s How They Did, Plus 3 New Picks."
              },
              {
                "id": 141164545,
                "url": "https://finnhub.io/api/news?id=44f469db2ba4ab532ebcd6bf5ad440c04106be3c1ee1309f5134b752b52ce9e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson has seen its analyst fair value estimate move from US$181.23 to US$189.58, signaling a refreshed price target framework that investors are watching closely. This shift reflects how recent research is weighing the solid fiscal Q3 beat, product updates, and mixed views on 2027 utilization and margin risk. As you read on, you will see how these moving pieces shape the evolving narrative around Becton Dickinson and what that could mean for your own assessment of the stock. Stay...",
                "category": "company",
                "datetime": 1786252239,
                "headline": "Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views"
              },
              {
                "id": 141163150,
                "url": "https://finnhub.io/api/news?id=3000ac72501f771df79c06aee4f6d979ea4e11e11a74e9ed7a616f07a0d55fa7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company recently reported third-quarter fiscal 2026 results, with sales rising to US$4,983 million while net income fell to US$377 million, and modestly raised its full-year outlook for low single-digit plus GAAP revenue growth. Alongside these earnings, BD highlighted strong momentum in biologic drug delivery and GLP-1–related partnerships, including a new semaglutide pen collaboration with EMS in Brazil, underscoring the growing role of its Vystra Injection Pen...",
                "category": "company",
                "datetime": 1786234852,
                "headline": "Why Becton Dickinson (BDX) Is Up 6.8% After Q3 Beat And GLP-1 Delivery Partnerships"
              },
              {
                "id": 141155626,
                "url": "https://finnhub.io/api/news?id=7aaf67e135bd6274b8612d323ca1d2397a69f47c073f137a08120d6f7e9e50af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BDX beats expectations with 4.4% FX-neutral revenue growth, raises full-year EPS guidance, and outlines strategic plans to navigate fiscal 2027 headwinds.",
                "category": "company",
                "datetime": 1786158249,
                "headline": "Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and ..."
              },
              {
                "id": 141154801,
                "url": "https://finnhub.io/api/news?id=0a764ba0efd44dd70913281762017bc2baaef505ad608774f1f0fbf255c2210c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (NYSE:BDX) reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company’s expectations. Chairman, Chief Executive Officer and President Tom Po",
                "category": "company",
                "datetime": 1786147446,
                "headline": "Becton, Dickinson and Company Q3 Earnings Call Highlights"
              },
              {
                "id": 141158740,
                "url": "https://finnhub.io/api/news?id=93335069d097313afdab9d14196b9c96d2ef845b532225f993b1af6b090e16e5",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Citigroup  analyst Joanna Wiensch   maintains Becton Dickinson (NYSE:BDX) with a Buy and raises the price target from $198 to $204.",
                "category": "company",
                "datetime": 1786121559,
                "headline": "Citigroup Maintains Buy on Becton Dickinson, Raises Price Target to $204"
              },
              {
                "id": 141158741,
                "url": "https://finnhub.io/api/news?id=31a9b4919c18547a9b8bd5ef827a40b3daa1617e0e2becaf09c74e488800f537",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "RBC Capital  analyst Kendall Au   maintains Becton Dickinson (NYSE:BDX) with a Sector Perform and raises the price target from $175 to $180.",
                "category": "company",
                "datetime": 1786113213,
                "headline": "RBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $180"
              },
              {
                "id": 141158742,
                "url": "https://finnhub.io/api/news?id=3bde1141158f3b7a3750d2fa040f5a2ae98649300b1fe98e295bd98b3b7d6b5d",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Piper Sandler  analyst Jason Bednar   maintains Becton Dickinson (NYSE:BDX) with a Neutral and raises the price target from $161 to $175.",
                "category": "company",
                "datetime": 1786107231,
                "headline": "Piper Sandler Maintains Neutral on Becton Dickinson, Raises Price Target to $175"
              },
              {
                "id": 141147954,
                "url": "https://finnhub.io/api/news?id=d8292bbb157226aa77041fa7a7059124e0b40777a1403718ae374893f6c6da7f",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Wells Fargo  analyst Lawrence Biegelsen   maintains Becton Dickinson (NYSE:BDX) with a Equal-Weight and raises the price target from $161 to $170.",
                "category": "company",
                "datetime": 1786096339,
                "headline": "Wells Fargo Maintains Equal-Weight on Becton Dickinson, Raises Price Target to $170"
              },
              {
                "id": 141140759,
                "url": "https://finnhub.io/api/news?id=c2380f33c400460b03b7dd46a632a72725e9a5d1cc04c7779536e1dbc8835480",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Moby summary of Becton, Dickinson and Company's Q3 2026 earnings call",
                "category": "company",
                "datetime": 1786049172,
                "headline": "Becton, Dickinson and Company Q3 2026 Earnings Call Summary"
              },
              {
                "id": 141140760,
                "url": "https://finnhub.io/api/news?id=ee6d3d007ea52ed7ece2e1ffe250bd9d757cc332572d23d1547242731970e0d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.",
                "category": "company",
                "datetime": 1786038120,
                "headline": "BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down"
              },
              {
                "id": 141135533,
                "url": "https://finnhub.io/api/news?id=9cb546f94b34511297f2c084b2fb2d0efcc05c53fd0cdd68ff0bd61222c83c08",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) raised its full-year earnings guidance as the medical device maker's third-qu",
                "category": "company",
                "datetime": 1786030368,
                "headline": "Becton Dickinson Lifts Full-Year Profit Outlook as Third-Quarter Results Top Views"
              },
              {
                "id": 141136868,
                "url": "https://finnhub.io/api/news?id=02cd60be2ff7e9866b770880616d492cdf9062e40615a3698bc80ddc8e7bbf03",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsShawn Bevec - Senior VP of Investor RelationsThomas...",
                "category": "company",
                "datetime": 1786023895,
                "headline": "Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript"
              },
              {
                "id": 141135694,
                "url": "https://finnhub.io/api/news?id=fee587bfe7cc55c7d9e2a1c32fd4fdaa9fa5d9caceb4f180895477aa8236066c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
                "category": "company",
                "datetime": 1786023005,
                "headline": "Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 141134260,
                "url": "https://finnhub.io/api/news?id=63e7ebf4b3fdb691514dc10a02417a08e2a08908101ab5f3a7ccd8faf977d0a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) delivered earnings and revenue surprises of +2.87% and +1.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1786018803,
                "headline": "Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates"
              },
              {
                "id": 141133334,
                "url": "https://finnhub.io/api/news?id=b991a9a6f55b83499acecfc65176f9d762825ca8c7c188e203b55f4c84ee7323",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "US equity markets were mostly pointing higher before the opening bell Thursday as investors assess p",
                "category": "company",
                "datetime": 1786017164,
                "headline": "Stocks Mostly Up Pre-Bell as Investors Weigh Potential Iran-Oman Hormuz Deal, Await More Earnings"
              },
              {
                "id": 141140471,
                "url": "https://finnhub.io/api/news?id=6840bd968804540603a66708da09117efef91d1fced5b4de30716bc660745b81",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/06/Becton-Dickinson.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Becton Dickinson raises 2026 adjusted EPS guidance after reporting Q3 revenue growth across core medical and interventional business segments.",
                "category": "company",
                "datetime": 1786017100,
                "headline": "Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook"
              },
              {
                "id": 141133058,
                "url": "https://finnhub.io/api/news?id=16cb6c29a10d6f7bbf90de0409addee103846d9be432d7d80b7d2678e69c787f",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp",
                "source": "ChartMill",
                "related": "BDX",
                "summary": "BD's fiscal Q3 revenue of $4.983B and EPS of $3.23 edged past consensus, leaving results in line with expectations; shares ticked up modestly pre-market.",
                "category": "company",
                "datetime": 1786015778,
                "headline": "Becton Dickinson (NYSE:BDX) Reports In-Line Fiscal Q3 Results"
              },
              {
                "id": 141133368,
                "url": "https://finnhub.io/api/news?id=76c0f02439328704b4743624e0fd526a9736120936b9086748eb71b285ab0448",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 third quarter, which ended June 30, 2026.",
                "category": "company",
                "datetime": 1786012200,
                "headline": "BD Reports Third Quarter Fiscal 2026 Financial Results"
              },
              {
                "id": 141133646,
                "url": "https://finnhub.io/api/news?id=66fb62ed2773f639b52e3136ed311cf58b65d448ac803bc26e8a6616714823ae",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "2026-08-06. The following slide deck was published by Becton, Dickinson and Company in conjunction with their 2026 Q3 earnings call.",
                "category": "company",
                "datetime": 1786005327,
                "headline": "Becton, Dickinson and Company 2026 Q3 - Results - Earnings Call Presentation"
              },
              {
                "id": 141140472,
                "url": "https://finnhub.io/api/news?id=9c331d50fe25bfa1beebb5d45ef86c316090daea57cc55c8709ecd70289407b4",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Becton, Dickinson (NYSE:BDX) reported quarterly earnings of $3.23 per share which beat the analyst consensus estimate of $3.14 by 2.87 percent. This is a 12.23 percent decrease over earnings of $3.68 per share from the",
                "category": "company",
                "datetime": 1785997872,
                "headline": "Becton, Dickinson Q3 Adj. EPS $3.23 Beats $3.14 Estimate, Sales $4.983B Beat $4.887B Estimate"
              },
              {
                "id": 141140473,
                "url": "https://finnhub.io/api/news?id=ca591617976e47fafc2c2f6912a47754d54dd100e3108dff3fb0501ff7a33e5d",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Becton Dickinson (NYSE:BDX) raises FY2026 Adj EPS guidance from $12.52-$12.72 to $12.62-$12.72 vs $12.61 analyst estimate..",
                "category": "company",
                "datetime": 1785997866,
                "headline": "Becton Dickinson Raises FY2026 Adj EPS Guidance from $12.52-$12.72 to $12.62-$12.72 vs $12.61 Est"
              },
              {
                "id": 141125909,
                "url": "https://finnhub.io/api/news?id=4cc57192c03dfc0eedad44bf9d950f4c8edb9fb26d63e7e6f813fcb1fdc036e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BDX's Medical Essentials and Interventional strength may drive third-quarter fiscal 2026 results, but China, vaccines and projected declines weigh on expectations.",
                "category": "company",
                "datetime": 1785952920,
                "headline": "Can Segment Strength Offset Headwinds for BD Stock Before Q3 Earnings?"
              },
              {
                "id": 141140474,
                "url": "https://finnhub.io/api/news?id=d325a9f5bd181acf3129bdc5dc9354280a192738701ae74f4c1cec0abdddb7af",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "TD Cowen  analyst Joshua Jennings   maintains Becton Dickinson (NYSE:BDX) with a Hold and raises the price target from $163 to $182.",
                "category": "company",
                "datetime": 1785944556,
                "headline": "TD Cowen Maintains Hold on Becton Dickinson, Raises Price Target to $182"
              },
              {
                "id": 141122027,
                "url": "https://finnhub.io/api/news?id=f1d1915a2509dd798d026c32af986df95edfa0b511ea839bd9bf55a26674194c",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-intraosseous-needle-set-issue-becton-dickinson",
                "category": "company",
                "datetime": 1785850604,
                "headline": "FDA Issues Early Alert On BD Intraosseous Needle Sets; Reports Linked To 45 Serious Injuries, 4 Deaths, Recommends Immediate Removal Of Affected Lots"
              },
              {
                "id": 141110269,
                "url": "https://finnhub.io/api/news?id=554b67fd3b01fb596ef77286d87b97ca8fc2a42ce9c2a815e97199064384d33c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
                "category": "company",
                "datetime": 1785849307,
                "headline": "Countdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS"
              },
              {
                "id": 141108853,
                "url": "https://finnhub.io/api/news?id=8405c26eeeec9fefd51c2130a22626fb4d90702946564931c2d122d5d9ccfbf8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Waters Corporation (NYSE:WAT) reported second-quarter 2026 results that came in ahead of Wall Street expectations, supported by strong organic growth across its pharmaceutical and industrial businesses. The analytical instruments and diagnostics company’s shares were little changed in pre-market trading, edging up 0.",
                "category": "company",
                "datetime": 1785846125,
                "headline": "Waters Exceeds Second-Quarter Forecasts as Broad-Based Growth Continues"
              },
              {
                "id": 141108854,
                "url": "https://finnhub.io/api/news?id=eec0907e2f8b9c8eb9e3bed6f2d93340eec0da9481493f546717a71608474488",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Henry Schein (HSIC) delivered earnings and revenue surprises of +4.10% and +2.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785841801,
                "headline": "Henry Schein (HSIC) Q2 Earnings and Revenues Beat Estimates"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 66,
            "discarded_article_count": 52
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.7,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": true,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(21.8%→6.2%)；跌縮量(近10日4日)；站上MA50；升放量(近10日2日)；Ready=Y；Confirm=Y",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1803236.6666666667,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1753980,
              "avg_vol_20": 1807565,
              "avg_vol_30": 1803236.6666666667,
              "range_pct_10": 0.06159346736348119,
              "range_pct_20": 0.13363914515784983,
              "range_pct_30": 0.21832341616894202,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9726843028554211,
              "dist_to_20d_high": 0.028746085869256706,
              "down_shrink_days": 4,
              "breakout_level_20d": 193.070007,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.2821202986115755
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.084524317406143,
              "turnoverUsdM": 276.48848896000004,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BDX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 179.7022,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4.2,
            "take_profit_price": 196.896,
            "target_multiplier": 1.9,
            "technical_strength": 1.78,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.169048634812286,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.BDX",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 3.9089,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.08
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 61.77
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1723
    },
    "kdj": {
      "d": 58.4,
      "j": 4.51,
      "k": 40.43,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 67.46
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 21777648,
      "recentSlope": -68565.2,
      "previousSlope": 304500
    },
    "rsi": 61.46,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 191.9068,
      "position": "SAR喺價上",
      "distancePct": 2.34,
      "previousTrend": "下降"
    },
    "ma50": 168.5376,
    "macd": {
      "macd": 5.93125951047017,
      "trend": "中性偏多",
      "signal": 6.875822277297642,
      "histogram": -0.9445627668274721
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 184.6238,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 29
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.84,
      "score": 4,
      "avgVolume": 1754387,
      "currentVolume": 1474448
    },
    "derived": {
      "ma20": 185.2565,
      "ma50": 168.5376,
      "prevClose": 187.12,
      "avgVolume10": 1684975,
      "avgVolume20": 1754387,
      "changePercent": 0.21,
      "avgVolumeForScore": 1754387
    },
    "ma_cross": {
      "ma20": 185.2565,
      "ma50": 168.5376,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 184.4135,
      "prevMa50": 167.6656,
      "spreadPct": 9.92,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 176.2456,
      "upper": 194.2674,
      "position": "上半部"
    },
    "rsi_short": 33.13,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.84
    }
  }
}

{
  "close": 187.52,
  "volume": 1474448,
  "changePercent": 0.21
}